Core Insights - OnKure Therapeutics has raised approximately $150 million through a private placement to advance its next-generation PI3Kα pan-mutant inhibitors for breast cancer and vascular anomalies, with plans to file INDs in the first half of 2027 [1][2][6] Financing Details - The financing was led by Access Biotechnology, with participation from various new and existing investors, including BVF Partners LP, RA Capital Management, and others [2][9] - OnKure plans to use the net proceeds for preclinical and clinical development of its PI3Kα inhibitors, as well as for working capital and general corporate purposes [2][3] Product Development - The company is focusing on two next-generation PI3Kα pan-mutant programs: OKI-345 for breast cancer and OKI-355 for vascular anomalies, designed to selectively inhibit mutant PI3Kα while sparing wildtype PI3Kα [4][5] - These candidates aim to provide a wider therapeutic index and avoid class-limiting toxicities, with potential for deep and durable responses [4] Clinical Trials - The PIKture-01 trial is a phase 1a/1b study evaluating the safety and efficacy of OKI-219, with enrollment completed for both single-agent and combination therapies [7][8] - OnKure is not planning further development of OKI-219 independently at this time, focusing instead on its pan-mutant inhibitors [8] Leadership Changes - Liam Ratcliffe, Head of Biotechnology at Access Biotechnology, has joined OnKure's Board of Directors, which is expected to enhance the company's strategic direction [10]